These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1988519)

  • 41. Murine hybridoma antibodies enhance bactericidal activity of human cord blood against K1 Escherichia coli strains.
    Kim KS; Cross AS; Kaufmann B; Zollinger W; Sadoff J
    Pediatr Res; 1990 Dec; 28(6):667-70. PubMed ID: 1704500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. B-1a cell origin of the murine B lymphoma line BCL1 characterized by surface markers and bacterial reactivity of its surface IgM.
    Koganei S; Ito M; Yamamoto K; Matsumoto N
    Immunol Lett; 2005 May; 98(2):232-44. PubMed ID: 15860223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunization with an anti-idiotypic antibody against the broadly lipopolysaccharide-reactive antibody WN1 222-5 induces Escherichia coli R3-core-type specific antibodies in rabbits.
    Brade L; Heine H; Raina S; Klein G; Di Padova F; Brade H; Müller-Loennies S
    Innate Immun; 2012 Apr; 18(2):279-93. PubMed ID: 21844130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Escherichia coli antibodies in opsonisation and protection against infection.
    van Dijk WC; Verbrugh HA; van Erne-van der Tol ME; Peters R; Verhoef J
    J Med Microbiol; 1981 Nov; 14(4):381-9. PubMed ID: 7031250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibodies given orally in the neonatal period can affect the immune response for two generations: evidence for active maternal influence on the newborn's immune system.
    Lundin BS; Dahlman-Höglund A; Pettersson I; Dahlgren UI; Hanson LA; Telemo E
    Scand J Immunol; 1999 Dec; 50(6):651-6. PubMed ID: 10607314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of hybridoma immunoglobulin switch variants in the analysis of the protective properties of anti-lipopolysaccharide antibodies in Escherichia coli K1 infection.
    Pelkonen S; Pluschke G
    Immunology; 1989 Oct; 68(2):260-4. PubMed ID: 2680911
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relative opsonic and protective activities of antibodies against K1, O and lipid A antigens of Escherichia coli.
    Welch WD; Martin WJ; Stevens P; Young LS
    Scand J Infect Dis; 1979; 11(4):291-301. PubMed ID: 93778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Avidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6B.
    Sun Y; Hwang Yi; Nahm MH
    Infect Immun; 2001 Jan; 69(1):336-44. PubMed ID: 11119522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Studies on immunity against Escherichia coli K13 with monoclonal anti-K13 and anti-anti-K13.
    Söderström T; Ohman L; Stein K; Schneerson R; Vann WF; Hanson LA
    Infection; 1984; 12(4):309-12. PubMed ID: 6386695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epitopes of Escherichia coli alpha-hemolysin: identification of monoclonal antibodies that prevent hemolysis.
    Ji GE; O'Hanley P
    Infect Immun; 1990 Sep; 58(9):3029-35. PubMed ID: 1696938
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of Escherichia coli K1 colominic acid-specific murine antibodies that are cross-protective against Neisseria meningitidis groups B, C, and Y.
    Park IH; Lin J; Choi JE; Shin JS
    Mol Immunol; 2014 Jun; 59(2):142-53. PubMed ID: 24603121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opsonic activity of serum and whey from cows immunized with the ferric citrate receptor.
    Wise AJ; Hogan JS; Takemura K; Smith KL
    J Dairy Sci; 2003 Jan; 86(1):146-51. PubMed ID: 12613859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation between opsonic activity for various microorganisms and composition of gammaglobulin preparations for intravenous use.
    van Furth R; Leijh PC; Klein F
    J Infect Dis; 1984 Apr; 149(4):511-7. PubMed ID: 6202804
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models.
    Givner LB
    Pediatrics; 1990 Dec; 86(6):955-62. PubMed ID: 2123536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease.
    Hill HR; Kelsey DK; Gonzales LA; Raff HV
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S87-91. PubMed ID: 1728992
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Studies on immunity against Escherichia coli K13 with monoclonal anti-K13 and anti-anti-K13.
    Söderström T; Ohman L; Stein K; Schneerson R; Vann WF; Hanson LA
    Infection; 1985; 13 Suppl 2():S256-9. PubMed ID: 3902658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunoglobulin therapy of neonatal group B streptococcal infections: an overview.
    Fischer GW
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S13-6. PubMed ID: 3041355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endotoxemia in neonatal calves given antiserum to a mutant Escherichia coli (J-5).
    Morris DD; Cullor JS; Whitlock RH; Wickstrom M; Corbeil LB
    Am J Vet Res; 1986 Dec; 47(12):2554-65. PubMed ID: 3541706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1.
    Pluschke G; Achtman M
    Infect Immun; 1985 Aug; 49(2):365-70. PubMed ID: 2410365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bactericidal activity of two IgG2a murine monoclonal antibodies with distinct fine specificities for group B Neisseria meningitidis capsular polysaccharide.
    Hurpin CM; Carosella ED; Cazenave PA
    Hybridoma; 1992 Dec; 11(6):677-87. PubMed ID: 1284118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.